Bibliographie – Relistor

Bibliographie – Relistor
1. Association canadienne de soins palliatifs. Peut être consulté à l’adresse
suivante : http://www.chpa.net/home.htm
2. Association canadienne de soins palliatifs – fiche technique : Avril 2008.
3. Burge F et al. Primary care continuity and location of death for those with cancer.
Palliat Med 2003;6:911-918.
4. Pappagallo M et al. Incidence, prevalence, and management of opioid bowel
dysfunction. Am J Surg 2001;182 (suppl5): 11S-18S
5. Emanuel EJ et al. Palliative and end-of-life care. In: Kasper DL, Braunwald E,
Fauci AS, et al, eds. Harrison’s Principles of Internal Medicine. 16th ed. New
York, NY: McGaw-Hill:2005;53-66.
6. McMillan SC. Assessing and managing opiate-induced constipation in adults with
cancer. Cancer Control 2004;11:3-9.
7. Hanks G et al. Symptom Management. The management of pain: Opioid
Analgesic Therapy (316-341). In Oxford textbook of Palliative Medicine, 3rd Ed.
Oxford University Press, 2003.
8. Goldlist BJ et al. Constipation Can be Deadly. Canadian Family Physician
1992;38:2419-2421.
9. Miles CL et al. Laxatives for the management of constipation in palliative care
patients. Cochrane Database of Systematic Reviews 2006, Issue 4.
10. Jovey D et al. Use of opioid analgesics for the treatment of chronic non-cancer
pain – A consensus statement and guidelines from the Canadian Pain Society,
2002. Pain Research Management 2003; 8(suppl A):3A-12A.
11. McNicol ED et al. Mu-opioid antagonists for opioid-induced bowel dysfunction.
Cochrane Datase Syst Rev 2008;April16:CD006332.
12. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage
1990;5:362-367.
13. Berde C, Nurko S (editorial). Opioid side effects—mechanism-based therapy. N
Eng J Med 2008;358:2400-2.
14. Goodheart CR and Leavitt SB. Pain Treatment Topics August 2006. Peut être
consulté à l’adresse suivante : http://www.pain-topics.com.
15. Thomas J et al. Methylnaltrexoe for opioid-induced constipation in advanced
illness. N Engl J Med 2008;358:2332-43.
16. Ahmedzai SH Boland J. Constipation in people prescribed opioids. BMJ Clin Evid
2007;12:1-11.
17. Anon. Methylnaltrexone (MNTX). Drugs R D 2006;7(6):374-8.
18. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the
treatment of opiate-related constipation: A systematic review. J Pain Symptom
Manage 2007;35:547-65.
19. Berde C, Nurko S. Opioid side effects – mechanism-based therapy [editorial]. N
Engl J Med 2008;358(22):2400-2.
20. Boyd TA, Israel RJ. Treatment of opioid-induced constipation in hospice patients
with methylnaltrexone. [Abstract #8279]. 2004 ASCO Annual Meeting. Peut être
consulté à l’adresse suivante :
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview
=abst_detail_view&confID=26&abstractID=4368 .
21. DeHaven-Hudkins DL, DeHaven RN, Little PJ, Techner LM. The involvement of
the mu-opioid receptor in gastrointestinal pathophysiology: Therapeutic
opportunities for antagonism as this receptor. Pharmacology Therapeut
2008;117:162-87.
22. Santé Canada. Avis de conformité [base de données en ligne]. Peut être
consultée à l’adresse suivante : http://www.nocdatabase.ca/ .
23. Karver SB, Slatkin NE, Thomas J, Israel RJ. Methylnaltrexone treatment of
opioid-induced constipation in cancer patients. [abstract #9081] 2007 ASCO
Annual Meeting. Peut être consulté à l’adresse suivante :
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview
=abst_detail_view&confID=47&abstractID=35781 (Consulté le 20 mai 2008).
24. Kurz A, Sessler DI. Opioid-induced bowel dysfunction. Drugs 2003;63(7):649-71.
25. Lembo A. Peripheral opioids for functional GI disease: A reappraisal. Dig Dis
2006;24:91-8.
26. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioidinduced bowel dysfunction. Cochrane Database of Systematic Reviews 2008,
Issue 2. Art. No.: CD006332. DOI: 10.1002/14651858.CD006332.pub2.
2
27. Murphy BD, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric
emptying: A peripheral mechanism in humans. Anesthesiology 1997;87(4):76570. Peut être consulté à l’adresse suivante :
http://www.anesthesiology.org/pt/re/anes/fulltext.00000542-19971000000008.htm;jsessionid=L8XGgB41pr1BTy0L26p1gnJvgynGvjf7CZyTpNVJnHdcNL
s2Jjhs!195308708!181195628!8091!-1 .
28. Neyens R, Jackson KC II. Novel opioid antagonists for opioid-induced bowel
dysfunction and postoperative ileus. J Pain Pall Care Pharmacother
2007;21(2):27-33.
29. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous
methylnaltrexone for the treatment of opioid-induced constipation in patients with
advanced illness: A double-blind, randomized, parallel group, dosing- ranging
study. J Pain Symptom Manage 2008;35:458-68.
30. Reichle FM, Conzen PF. Methylnaltrexone, a new peripheral mu-receptor
antagonist for the prevention and treatment of opioid-induced extracerebral side
effects. Curr Opin Invest Drugs 2008;9(1):90-100.
31. Repchinsky C. Compendium des produits et spécialités pharmaceutiques.
Association des pharmaciens du Canada, Ottawa, ON. 2008.
32. Shaiova L, Rim F, Friedman D, Jadhi M. A review of methylnaltrexone, a
peripheral opioid receptor antagonist, and its role in opioid-induced constipation.
Pall Supportive Care 2007;5:161-6.
33. Thomas J. Cancer-related constipation. Curr Oncol Reports 2007:278-84.
34. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage
2008;35:103-13.
35. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced
constipation in advanced illness. N Engl J Med 2008;358:2332-43.
36. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced
constipation in advanced illness [supplementary appendix]. Peut être consulté à
l’adresse suivante : http://content.nejm.org/cgi/content/full/358/22/2332/DC1
37. Thomas J, Libman A, Slatkin N, et al. A phase II double-blind placebo-controlled
trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in
advanced medical illness (AMI) .[abstract #8003]. 2005 ASCO Annual Meeting.
Peut être consulté à l’adresse suivante :
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview
=abst_detail_view&confID=34&abstractID=32585 .
3
38. Thomas J, Portenoy R, Moehl M, et al. A phase II randomized dose-finding trial
of methylnaltrexone for the relief of opioid-induced constipation in hospice
patients. 2003 ASCO Annual Meeting. Peut êre consulté à l’adresse suivante :
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview
=abst_detail_view&confID=23&abstractID=103785 .
39. Centre collaborateur de l'OMS pour la méthodologie sur l'établissement des
statistiques concernant les produits médicamenteux. Codes ATC 2008 [base de
données en ligne]. Peut être consultée à l’adresse suivante :
http://www.whocc.no/atcddd/ .
40. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel
dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41:98493.
41. Yuan CS, Doshan H, Charney MR, et al. Tolerability, gut effects, and
pharmacokinetics of methylnaltrexone following repeated intravenous
administration in humans. J Clin Pharmacol 2005;45:538-46.
42. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA
2000;284(11):1383-4.
43. Yuan CS, Foss JF, O’Connor M, et al. Efficacy of orally administered
methylnaltrexone in decreasing subjective effects after intravenous morphine.
Drug Alcohol Depend 1998;52:161-5.
44. Yuan CS, Foss JF, O’Connor M, et al. Effects of enteric-coated
methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time.
Clin Pharmacol Ther 2000;67:398-404.
45. Yuan CS, Foss JF, O’Connor M, et al. Effects of intravenous methylnaltrexone on
opioid-induced gut motility and transit time changes in subjects receiving chronic
methadone therapy: a pilot study. Pain 1999;83:631-5.
46. Yuan CS, Foss JF, O’Connor M, et al. Methylnaltrexone for reversal of
constipation due to chronic methadone use. JAMA 2000;283(3):367-72.
47. Yuan CS, Foss JF, O’Connor M, et al. Methylnaltrexone prevents morphineinduced delay in oral-cecal transit time without affecting analgesia: A doubleblind randomized placebo-controlled trial. Clin Pharmacol Ther 1996;59:469-75.
48. Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral
methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.
Clin Pharmacol Ther 1997;61:467-75.
4
49. Yuan CS, Moss J, Wei G, et al. Methylnaltrexone (MNTX) for chronic opioidinduced constipation. 2002 ASCO Annual Meeting. Peut être consulté à l’adresse
suivante :
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview
=abst_detail_view&confID=16&abstractID=1501
50. Yuan C-S, Wei G, Foss JF, et al. Effects of subcutaneous methylnaltrexone on
morphine-induced peripherally mediated side effects: A double-blind randomized
placebo-controlled trial. J Pharmacol Exp Therapeut 2002;300:118-23.
51. Methylnaltrexone (Relistor). London New Drugs Group APC/DTC Briefing
Document. July 2008. Peut être consulté à l’adresse suivante :
http://www.druginfozone.nhs.uk/Record%20Viewing/viewRecord.aspx?id=59489
9
52. Foundation for Medical Practice Education. Constipation. Pharmacological
Treatment of Constipation. Appendix 2. Peut être consulté à l’adresse suivante :
http://www.fmpe.org/en/documents/doc_aids/Constipation-Appendix-2.pdf
5